文献速递前列腺癌

针对前列腺癌幸存者的定制电子生存护理计划:一项多中心随机对照试验

A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial.
PubMed 文献 · J Urol · 2024-12-20

该研究在加拿大3个中心开展前瞻性平行1:1随机对照试验,纳入189例早期前列腺癌幸存者,评估定制电子生存护理计划(PCa-SCP)与常规护理的效果。主要结局患者激活度未见显著组间随时间差异,但信息满意度和部分自我管理支持维度有显著改善。作者认为PCa-SCP可能是提升幸存者照护质量的有价值工具。

要点

  • PCa-SCP对患者激活度(PAM-13)无显著组间随时间差异。
  • 信息满意度在基线与6个月、基线与12个月均显著优于常规护理。
  • 社会整合与支持、技能获取在基线与6个月有显著组间差异。

核心结论

  • PCa-SCP干预对患者激活度无显著影响,但提高了信息满意度和部分自我管理支持方面的得分。
  • 作者认为,单独提供SCP的获益仍不明确,但PCa-SCP可能是可在此基础上构建的有价值工具,作为综合方法的一部分以提升前列腺癌幸存者照护质量。

研究设计与样本

  • 前瞻性、平行1:1随机对照试验,在加拿大3个中心开展。
  • 纳入早期前列腺癌幸存者189例(应答率64%),随机接受PCa-SCP干预或常规护理。
  • 评估时间点为基线、6个月和12个月。
  • 主要结局为患者激活度(Patient Activation Measure-13)的变化。
  • 次要结局包括信息满意度、自我管理支持、前列腺特异性生活质量、癌症担忧、医疗资源利用和健康行为。

主要发现

  • 主要结局患者激活度分析未检测到显著的组间随时间差异。
  • 信息满意度在基线与6个月间存在显著组间差异(均值[95%CI]:7.13[5.53-8.71];效应量0.34;P<.001),基线与12个月间亦显著(4.91[3.06,7.06];效应量0.19;P<.001)。
  • 社会整合与支持在基线与6个月间存在显著组间差异(均值[95%CI]:0.16[0.06-0.26];效应量0.25;P=.002)。
  • 技能与技术获取在基线与6个月间存在显著组间差异(均值[95%CI]:0.12[-0.02至0.24];效应量0.33;P=.05)。
  • 未检测到其他组间随时间差异。

关键数值与推荐

  • 主要结局患者激活度(PAM-13)变化:无显著组间随时间差异。
  • 信息满意度基线与6个月:均值7.13(95%CI 5.53-8.71),效应量0.34,P<.001。
  • 信息满意度基线与12个月:均值4.91(95%CI 3.06-7.06),效应量0.19,P<.001。
  • 社会整合与支持基线与6个月:均值0.16(95%CI 0.06-0.26),效应量0.25,P=.002。
  • 技能与技术获取基线与6个月:均值0.12(95%CI -0.02至0.24),效应量0.33,P=.05。

临床怎么用

  • 原文结论未据此给出具体临床推荐。
  • 作者认为PCa-SCP干预可能是可在此基础上构建的有价值工具,作为综合方法的一部分以提升前列腺癌幸存者照护质量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Although the provision of a survivorship care plan (SCP) has been recommended after prostate cancer (PCa) treatment, there have been no randomized controlled trials to examine their impact. The objective of this study was to evaluate the effect of a tailored PCa-SCP intervention provided to early-stage PCa survivors. MATERIALS AND METHODS: A prospective, parallel 1:1 randomized controlled trial was conducted at 3 sites across Canada. Early-stage PCa survivors were randomized (n = 189; 64% response rate) to receive PCa-SCP intervention or usual care. Assessments were performed at baseline, 6 months, and 12 months. The primary outcome was change in patient activation (Patient Activation Measure-13); secondary outcomes included satisfaction with information, self-management support, prostate-specific quality of life, cancer worry, health care utilization, and health behaviors. RESULTS: For the primary patient activation analyses, no significant group-by-time differences were detected. There were significant between-group differences in (1) satisfaction with information from baseline to 6 months (mean [95% CI]: 7.13 [5.53-8.71]; effect size [ES], 0.34; P < .001) and baseline to 12 months (4.91 [3.06, 7.06]; ES, 0.19; P < .001); (2) social integration and support from baseline to 6 months (mean [95% CI]: 0.16 [0.06-0.26]; ES, 0.25; P = .002); and (3) skill and technique acquisition from baseline to 6 months (mean [95% CI]: 0.12 [-0.02 to 0.24]; ES, 0.33; P = .05). No other group-by-time differences were detected. CONCLUSIONS: The PCa-SCP intervention did not have a significant effect on patient activation but did increase satisfaction with information and some aspects of self-management support. Although the benefits of the provision of an SCP alone remain unclear, the PCa-SCP intervention is likely a valuable tool that can be built upon as part of a comprehensive approach to enhance the quality of care for PCa survivors. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03017456.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Jones JM, Matthew A, Tanguay S, et al. A Tailored Electronic Survivorship Care Plan for Prostate Cancer Survivors: A Multicenter Randomized Controlled Trial. J Urol. 2024. PMID: 39705576. doi:10.1097/JU.0000000000004359

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。